Immunic, Inc. (IMUX)
Immunic eyes key data readout from multiple sclerosis trial in 2025
Immunic Inc (NASDAQ:IMUX) has reflected on key milestones achieved in 2024, including advancing its novel therapy, vidofludimus calcium, toward key data readouts and securing significant funding to progress its clinical programs. In a statement, the company said it expects top-line data from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis (PMS) in April 2025.
Immunic's IMU-856 shows potential in gastrointestinal health trials - ICYMI
Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr. Andreas Muehler talked with Proactive about the publication of the company's Phase 1 and Phase 1b clinical trial results for IMU-856 in The Lancet Gastroenterology & Hepatology.
Immunic reports positive Phase 1 results for celiac disease therapy published in The Lancet
Immunic Inc (NASDAQ:IMUX) announced that data from its phase 1/1b clinical trial for IMU-856, a small molecule targeting SIRT6, has been published in The Lancet Gastroenterology & Hepatology. The study, led by Dr James Daveson, a gastroenterologist with Wesley Research Institute in Australia, evaluated IMU-856's safety and efficacy in patients with celiac disease.
Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript
Immunic, Inc. (NASDAQ:IMUX ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Jessica Breu - Vice President Investor Relations and Communications Daniel Vitt - Chief Executive Officer and Director Glenn Whaley - Chief Financial Officer Jason Tardio - President and Chief Operating Officer Conference Call Participants William Wood - B. Riley Matt Cowper - Leerink Partners Matt Kaplan - Ladenburg Operator Good morning, and welcome to Immunic's Third Quarter 2024 Earnings Call.
Immunic highlights progress in multiple sclerosis programs, targets 2025 milestones
Immunic Inc (NASDAQ:IMUX) ended the third quarter with over $59 million in cash to advance its key clinical programs, including its lead candidate, vidofludimus calcium (IMU-838), for multiple sclerosis (MS). During the third quarter ended September 30, 2024, the firm advanced both its phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and a twin phase 3 ENSURE trials in relapsing multiple sclerosis (RMS) looking at orally available lead asset, nuclear receptor related 1 (Nurr1) activator, IMU-838.
Immunic Phase 3 MS study advances following positive recommendation from independent committee
Immunic Inc (NASDAQ:IMUX) announced a positive outcome from the interim futility analysis of its Phase 3 ENSURE program which is investigating its lead asset vidofludimus calcium in relapsing multiple sclerosis (RMS). The company said an Independent Data Monitoring Committee (IDMC) reviewed unblinded data and concluded that the trials had not met futility criteria, recommending that the study continue as planned without any changes.
Immunic highlights lead asset's promise in multiple sclerosis at ECTRIMS Congress
Immunic Inc (NASDAQ:IMUX) announced that it is presenting key data for its lead asset vidofludimus calcium at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), which has highlighted its therapeutic potential in multiple sclerosis (MS). Vidofludimus calcium consistently reduced neurofilament light chain (NfL) levels in the Phase 2 CALLIPER trial, suggesting it may slow disease progression across all progressive MS subtypes, the company reported.
Immunic drug targeting post-COVID syndrome in Phase 2 trial - ICYMI
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler joined Proactive to discuss a research update for the company's lead compound vidofludimus calcium. Vidofludimus calcium is being supplied for an investigator-sponsored Phase 2 clinical trial focused on treating post-COVID syndrome (PCCS).
Immunic reports first patient enrolled in investigator-sponsored post-COVID syndrome trial
Immunic Inc (NASDAQ:IMUX) announced that the first patient has been enrolled in an investigator-sponsored Phase 2 trial of its lead asset vidofludimus calcium for post-COVID syndrome. The RAPID_REVIVE study is sponsored by Goethe University Frankfurt, Germany, with funding received via a grant from the German Federal Ministry of Education and Research.
Immunic to highlight lead asset's promise at upcoming Multiple Sclerosis R&D Day
Immunic Inc (NASDAQ:IMUX) announced that it will be hosting a Multiple Sclerosis (MS) Research and Development (R&D) Day on September 10 featuring discussions on the company's lead drug asset vidofludimus calcium potential as a treatment for both relapsing and progressive MS patients. The company's management team, including CEO Daniel Vitt, COO Jason Tardio, chief medical officer Andreas Muehler, and chief scientific officer Hella Kohlhof will be joined by MS industry experts to discuss the MS space and vidofludimus calcium's promise.
Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript
Immunic, Inc. (NASDAQ:IMUX ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Jessica Breu - VP, IR & Communications Daniel Vitt - CEO Glenn Whaley - CFO Jason Tardio - COO Conference Call Participants Yasmeen Rahimi - Piper Sandler Matt Kaplan - Ladenburg Thalmann Tom Smith - Leerink Partners Tyler Bussian - Brookline Madison El-Saadi - B. Riley Jessica Breu Good morning, and welcome to Immunic's Second Quarter 2024 Earnings Call.
Immunic strengthens leadership team as MS trials advance toward key milestones
Immunic Inc (NASDAQ:IMUX) has highlighted clinical and operational progress achieved during the second quarter, which ended June 30, 2024, and the subsequent period. The biotechnology firm has welcomed experienced multiple sclerosis drug commercialization executive Jason Tardio as its chief operating officer and president and appointed senior pharmaceutical executive Simona Skerjanec to its board of directors.
